TAMOXIFEN AND FLUOXYMESTERONE IN ADVANCED BREAST-CANCER - A CONTROLLED CLINICAL-TRIAL
- 1 January 1980
- journal article
- research article
- Vol. 64 (1), 117-121
Abstract
Postmenopausal women (79) with stage IV breast cancer and no previous endocrine therapy or chemotherapy received tamoxifen or fluoxymesterone in an open randomized cross-over trial. The overall remission rate was 30% with tamoxifen as the 1st course of treatment and 19% with fluoxymesterone as the 1st course of treatment. Bone metastases were seen in 21 patients receiving tamoxifen and in 20 patients receiving fluoxymesterone. There were 6 and 5 remissions in these 2 groups, respectively. The time to the 1st change in therapy was significantly longer for the tamoxifen group (P = 0.003). The survival of the patients who received tamoxifen as the 1st course of endocrine treatment was better (P = 0.05).This publication has 5 references indexed in Scilit:
- Antihormone treatment of stage IV breast cancerCancer, 1979
- Assessment of response to therapy in advanced breast cancerBritish Journal of Cancer, 1977
- Isoelectric focusing of estradiol receptor protein from human mammary carcinoma—a comparison to sucrose gradient analysisEuropean Journal of Cancer (1965), 1976
- EFFECTS OF ESTROGENS AND ANTIESTROGENS ON HORMONE-RESPONSIVE HUMAN BREAST-CANCER IN LONG-TERM TISSUE-CULTURE1976
- Cyclophosphamide (Cytoxan). Proceedings of a Symposium (London), October 1963.Annals of Internal Medicine, 1965